Tag Archives: IASLC

Opdivo as Second-Line Treatment Option for Mesothelioma: Promising New Data

second-line treatment option

A new study suggests that the cancer drug Opdivo could be an effective second-line treatment option for people with relapsed mesothelioma. Right now, people whose mesothelioma comes back after treatment do not have an approved second-line treatment option.  The news on Opdivo comes from the first ever placebo-controlled phase 3 trial of patients with relapsed mesothelioma. It shows that the drug significantly improved overall survival for these patients. It also increased the time it took for patients’ cancer to get worse. Details of the CONFIRM Trial The trial of this proposed second-line treatment option for mesothelioma was called CONFIRM. It involved 332 mesothelioma patients from 24 UK cancer centers. The patients already had at least one treatment. Two thirds of … Continue reading Opdivo as Second-Line Treatment Option for Mesothelioma: Promising New Data »

First-Line Keytruda Treatment May Support Longer Mesothelioma Survival

first-line Keytruda treatment

New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona.  The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer.  Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line … Continue reading First-Line Keytruda Treatment May Support Longer Mesothelioma Survival »

Mesothelioma Staging Guidelines May Need Revisions

The International Association for the Study of Lung Cancer (IASLC) says the current strategy for staging malignant pleural mesothelioma may need to be modified. According to an international team of IASLC member researchers, the current system, which was established by the International Mesothelioma Interest Group (IMIG) and has been widely used, has a number of flaws. First, in part because it was based on a retrospective analysis of a small group of mesothelioma surgical patients, it has limited value in clinical staging.  In addition, the IMIG mesothelioma staging guidelines use descriptors for lymph node involvement which the IASLC researchers say may not be relevant to mesothelioma. Because of these shortcomings, the IASLC has announced that it will work with the IMIG to … Continue reading Mesothelioma Staging Guidelines May Need Revisions »